We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Initiator of Colon Cancer Metastasis Identified

By LabMedica International staff writers
Posted on 29 Sep 2011
Print article
A recent study highlighted the role of the BVES (blood vessel epicardial substance) protein in the epithelial-mesenchymal transition (EMT) that occurs when the cells comprising a primary tumor begin to spread and metastasize.

The acquisition of a mesenchymal phenotype is a critical step in the metastatic progression of epithelial cancers. Adherens junctions (AJs) are required for suppressing EMT but less is known about the role of tight junctions (TJs) in this process. To elucidate further the factors that drive EMT, investigators at Vanderbilt University (Nashville, TN, USA) examined the function of BVES (also known as POPDC1 and POP1) in relation to the initiation of EMT.

BVES is a highly conserved, transmembrane protein that is involved in cell adhesion, cell motility, and most recently has been shown to play a role in vesicular transport. BVES is found in a wide variety of organisms (from flies to humans) and is a member of the evolutionarily conserved Popdc family of proteins. Although the precise molecular function of BVES is unknown, disruption of this protein results in a wide range of developmental defects and impaired cellular processes.

The investigators reported in the September 12, 2011, online edition of the Journal of Clinical Investigation that they had found that BVES was underexpressed in all stages of human colorectal carcinoma (CRC) and in adenomatous polyps, indicating that its suppression occurred early in transformation. At the genomic level, they found that the BVES promoter was heavily methylated, which silenced its expression. Treating cells that were undergoing EMT with a demethylating agent (the drug decitabine, which is currently used to treat myelodysplastic disorders) restored BVES expression. Renewed BVES expression caused the cells to become more epithelial in nature, and their prometastatic characteristics diminished.

“In cancer, typically the primary tumor does not kill you; it is the metastatic disease that proves lethal," said first author Dr. Christopher Williams, assistant professor of medicine and cancer biology at Vanderbilt University. “So, if targeting BVES could interfere with metastasis; that would be very exciting.”

Related Links:

Vanderbilt University


Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Progesterone Serum Assay
Progesterone ELISA Kit
New
Hepato Fibrosis Assays
Hepato Fibrosis Assays

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.